GlassScriptPhysician profile
Garland Tang
NPI 1518317973
$34,194.46
in general payments reported to CMS, 2019-2025
47 companies · $80.58 in 2025
The $80.58 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.92 · 2021: $566 · 2022: $2,248 · 2023: $23K · 2024: $8,734 · 2025: $80.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $3,586 · Travel and Lodging: $291 · Education: $6.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,450.00 |
| Food and Beverage | $3,586.07 |
| Travel and Lodging | $291.11 |
| Education | $6.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,723.07 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Alexion Pharmaceuticals, INC. | $471.43 | 2021-2024 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $430.08 | 2021-2024 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $426.66 | 2021-2024 | |
| Pfizer INC. | $419.71 | 2022-2024 | |
| Biogen, INC. | $364.83 | 2021-2024 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $308.05 | 2022-2025 | |
| Ucb, INC. | $284.10 | 2022-2024 | Briviact, Zilbrysq, Rystiggo |
| Neurelis, INC. | $253.26 | 2021-2024 | Valtoco |
| Eisai INC. | $225.43 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $222.63 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $196.56 | 2023-2024 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $141.73 | 2022 | |
| Celgene Corporation | $135.97 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $133.42 | 2023-2024 | Amyvid, Kisunla, Reyvow |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garland Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.